newsmetry
rusign inget started
macro

Citi keeps Buy on McDonald's and Edwards Lifesciences, lifts both targets

According to TradingView, Citigroup kept Buy ratings on McDonald's and Edwards Lifesciences on November 5 and raised their price targets to $315 and $117.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

On November 5, Citigroup kept its Buy rating on McDonald's and lifted its price target to $315 from $295, a rise of 6.8%. The target suggests about 13.3% upside from the previous close of $278.04. The same day, Citi maintained its Buy on Edwards Lifesciences and raised its target to $117 from $110, up 6.4%, implying roughly 16.0% upside from the $100.82 close.

TradingView, citing Benzinga data, also listed recent notes from other brokers. For McDonald's, targets in the latest five notes ranged from $280 to $307; for Edwards Lifesciences, from $106 to $120.

why it matters

Analyst target changes like these are routine and rarely move the broader market. For shareholders they show how one brokerage values the stocks, but the implied upside is the bank's own estimate, not a forecast of share price moves.

tags

Analyst RatingStockUnited States

instruments

McDonald'sEdwards Lifesciences

sources

  1. Citigroup maintains McDonald's at Buy, raises price target to $315 from $295 — TradingView, 5 November 2026 at 21:27 UTC
  2. Citigroup maintains Edwards Lifesciences at Buy, raises price target to $117 from $110 — TradingView, 5 November 2026 at 21:37 UTC
  3. Citigroup maintains Medline at Buy, raises price target to $47 from $45 — TradingView, 5 November 2026 at 21:48 UTC
  4. Citigroup maintains Cytokinetics at Buy, raises price target to $105 from $99 — TradingView, 5 November 2026 at 21:54 UTC
  5. Citigroup maintains Ball at Buy, raises price target to $77 from $75 — TradingView, 5 November 2026 at 21:52 UTC
  6. Citigroup maintains Royalty Pharma at Buy, raises price target to $78 from $70 — TradingView, 5 November 2026 at 21:49 UTC
  7. Citigroup maintains IDEAYA Biosciences at Buy, raises price target to $66 from $65 — TradingView, 5 November 2026 at 22:21 UTC
  8. Citigroup maintains Ligand Pharmaceuticals at Buy, raises price target to $402 from $397 — TradingView, 5 November 2026 at 22:22 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories